Category: Research

International survey on evidence for index lymph node surgery after neoadjuvant systemic therapy for stage III melanoma

Background: Neoadjuvant immunotherapy for resectable stage III melanoma has demonstrated promising outcomes in recent trials, prompting a change in clinical practice in many countries. Although therap…

Read more about 'International survey on evidence for index lymph node surgery after neoadjuvant systemic therapy for stage III melanoma'...


Holistic framework that advances understanding of melanoma pathogenesis and supports development of

Melanoma, a highly aggressive form of skin cancer, is shaped by a complex interplay of genetic, environmental, and lifestyle factors. This review provides a comprehensive synthesis of the macroscopic …

Read more about 'Life factors and melanoma: from the macroscopic state to the molecular mechanism'...


Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment response

Background:  Despite the success of combined cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) immune checkpoint blockade (cICB), the majority of patients…

Read more about 'Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment response'...


Pembrolizumab-related toxicity in patients with advanced melanoma at Wellington and Waikato hospitals

Aim: Pembrolizumab has revolutionised the treatment of melanoma. Immune checkpoint inhibitors (ICI) are well tolerated in trials, but the real-world incidence of toxicities and their management are n…

Read more about 'Pembrolizumab-related toxicity in patients with advanced melanoma at Wellington and Waikato hospitals'...


Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) meta…

Read more about 'Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma'...


Adjuvant cemiplimab therapy led to longer disease-free survival than placebo among patients at high risk for recurrence of cutaneous SCC

Background: Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has …

Read more about 'Adjuvant cemiplimab therapy led to longer disease-free survival than placebo among patients at high risk for recurrence of cutaneous SCC'...


Aotearoa’s skin cancer crisis: key challenges and opportunities for strengthening sun safety policy, drawing on recent research and strategic recommendations

Each year, Aotearoa New Zealand’s (NZ) health system treats tens of thousands of skin cancers, the country’s most common cancer. This places a significant and avoidable burden on our healthcare system…

Read more about 'Aotearoa’s skin cancer crisis: key challenges and opportunities for strengthening sun safety policy, drawing on recent research and strategic recommendations'...


Outcomes of solid organ transplant recipients with advanced cancers receiving immune checkpoint inhibitors

Importance:  Immune checkpoint inhibitors (ICIs) have improved overall survival in patients with advanced-stage cancers. However, data on their efficacy and safety in solid organ transplant recipients…

Read more about 'Outcomes of solid organ transplant recipients with advanced cancers receiving immune checkpoint inhibitors'...


Commercial sunbeds should be banned in the UK

Indoor tanning is experiencing a boom in popularity, particularly among Gen Z (born 1997-2012), with social media promoting sunbeds as integral to wellness. Recent surveys report that 28% of the UK pu…

Read more about 'Commercial sunbeds should be banned in the UK'...